5 citations
,
July 2019 in “Photodiagnosis and photodynamic therapy” Using tacalcitol ointment with photodynamic therapy may effectively treat follicular mucinosis with scalp hair loss.
February 2026 in “JAAD International”
25 citations
,
November 2022 in “British journal of dermatology/British journal of dermatology, Supplement” Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
November 2023 in “Journal of medical and health studies” Combining low-level laser therapy with scalp microneedling and a clobetasol solution significantly improves androgenetic alopecia.
51 citations
,
August 2015 in “Cochrane library” Methotrexate is not proven to maintain remission in ulcerative colitis.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
January 2025 in “Journal of Cutaneous Immunology and Allergy” Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.
Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.
June 2024 in “International Journal of Dermatology” Upadacitinib may effectively treat resistant lichen planopilaris.
Topical latanoprost acid at 0.05% concentration improved hair growth in women with androgenetic alopecia.
February 2026 in “Frontiers in Immunology” Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
August 2021 in “Journal of the American Academy of Dermatology” Oral baricitinib is effective and safe for treating alopecia areata.
1 citations
,
September 2024 in “Life” Combining fractionated CO2 laser with tacrolimus may help treat chronic alopecia areata.
June 2024 in “Archives of Medical Science” Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Upadacitinib effectively treats severe alopecia areata and is safe.
July 2023 in “Skin Research and Technology” Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.
8 citations
,
June 2021 in “Frontiers in Medicine” The combination of the excimer lamp and liquor carbonis detergens is more effective for scalp psoriasis than the lamp alone.
9 citations
,
April 1970 in “Biochemical pharmacology” Stilbamidine and hydroxystilbamidine inhibit enzyme release from lysosomes and have effects similar to cortisol and chloroquine.
November 2024 in “Circulation” GLP1-RAs may have higher reports of suicide and hair loss, but no strong evidence links them to these issues.
September 2021 in “Journal of skin and stem cell” Lactium, a milk protein, can help reduce symptoms of skin disorders linked to stress and anxiety without side effects.
1 citations
,
October 2025 in “Frontiers in Immunology” Avacopan is generally safe, with some minor side effects like nausea and fatigue.
July 1994 in “Annals of Pharmacotherapy” Cromolyn sodium's effectiveness for treating asthma in children under 2 is unclear, possibly more beneficial for older children, and further research is needed.
5 citations
,
May 2024 in “Journal of Allergy and Clinical Immunology Global” Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
20 citations
,
November 2009 in “European Journal of Dermatology” Latanoprost, a glaucoma treatment, was found ineffective in treating hair loss in eyebrows and eyelashes.
June 2026 in “Journal of health economics and outcomes research” Ritlecitinib is more effective and cost-efficient than baricitinib for severe alopecia areata.
January 2023 in “Indian Dermatology Online Journal” Bimatoprost and clobetasol are both effective for scalp hair loss, but bimatoprost works faster, has fewer side effects, and grows more colored hair.
2 citations
,
October 2021 in “Journal of Cosmetic Dermatology” Finasteride is more effective and satisfactory than montelukast for treating moderate acne in women.
March 2026 in “Journal of the American Academy of Dermatology” The treatment significantly improved lymphocytic cicatricial alopecia symptoms in most patients.
6 citations
,
May 2023 in “Drugs” Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.